Market Cap (In USD)
509.51 Million
Revenue (In USD)
-
Net Income (In USD)
-42.12 Million
Avg. Volume
241.38 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 12.12-48.31
- PE
- -
- EPS
- -
- Beta Value
- 0.0
- ISIN
- US89157D1054
- CUSIP
- -
- CIK
- 1827506
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Sandeep C. Kulkarni M.D.
- Employee Count
- -
- Website
- https://www.tourmalinebio.com
- Ipo Date
- 2021-05-07
- Details
- Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
More Stocks
-
MBLY3Mobly S.A.
MBLY3
-
SBC
-
002780
-
PRIF-PDPriority Income Fund, Inc.
PRIF-PD
-
TBURFTobu Railway Co., Ltd.
TBURF
-
LBS
-
KEPENFlour Mills Kepenos S.A.
KEPEN
-
ELIElia Group SA/NV
ELI